2-乙酰基-3-乙氧基-N-(4-三氟甲基苯基)丙烯酰胺 | 75706-11-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-乙酰基-3-乙氧基-N-(4-三氟甲基苯基)丙烯酰胺
• 英文名称: 2-ethoxymethyleneacetoacetyl-(4-trifluoromethyl)aniline
• 英文别名: 2-(Ethoxymethylidene)-3-oxo-N-[4-(trifluoromethyl)phenyl]butanamide
• CAS: 75706-11-5
• 化学式: C₁₄H₁₄F₃NO₃
• 分子量: 301.265
• InChiKey: GTSMPCBIUVYFCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-乙酰基-3-乙氧基-N-(4-三氟甲基苯基)丙烯酰胺 在 盐酸羟胺 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 来氟米特
  参考文献：
  名称：

  利用分子内氢键进行酰胺取代的β-氨基烯酮的高度（Z）选择性和无金属合成

  摘要：

  在本文中，我们报告了酰胺取代的β-氨基烯酮的无金属和分子内氢键（IMHB）定向（Z）选择性合成。系统地，我们已经使用单晶X射线结构和1D，2D NMR研究证实了双IMHB（C = O∙∙∙H‒N）在Z方向上的作用。仅通过过滤就可以实现高的立体选择性，原子效率，优异的收率和高纯度。我们避免了色谱柱纯化，并且在此过程中形成的副产物对环境友好。

  DOI：

  10.1039/c7gc00909g
• 作为产物：
  描述：

  对三氟甲基苯胺 在 乙酸酐 作用下， 以 甲苯 为溶剂， 生成 2-乙酰基-3-乙氧基-N-(4-三氟甲基苯基)丙烯酰胺
  参考文献：
  名称：

  Synthesis and immunosuppressant activity of pyrazole carboxamides

  摘要：

  A series of novel pyrazole carboxamides is disclosed that demonstrate strong immunosuppressant activity in rodent and human mixed leukocyte response (MLR) assays (IC50 < 1 mu M). The synthesis, biological activity, mode of action, and pharmacokinetic properties of this new lead series are discussed. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00501-0

文献信息

• Treatment of platelet derived growth factor related disorders such as cancers
  申请人：University of California

  公开号：US06331555B1

  公开（公告）日：2001-12-18

  The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

  本发明涉及能够抑制血小板源性生长因子受体（PDGF-R）活性的化合物，最好这些化合物还能抑制PDGF-R超家族的其他成员的活性，并且对PDGF-R超家族的成员具有选择性。PDGF-R超家族包括PDGF-R和PDGF-R相关激酶Flt和KDR。这些特色化合物在细胞培养中对降低PDGF-R活性以及最好地对一种或多种PDGF-R相关激酶具有活性。下面描述了一种特色化合物A10（见图1a）及其抑制体内肿瘤细胞生长的能力。利用本申请作为指南，可以获得其他能够抑制PDGF-R、最好是Flt和/或KDR的化合物。这些化合物最好用于治疗患有由不适当PDGF-R活性特征的细胞增殖紊乱症状的患者。
• Treatment of platelet derived growth factor related disorders such as
  申请人：Sugen Inc.

  公开号：US05990141A1

  公开（公告）日：1999-11-23

  The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

  本发明涉及一类可以抑制血小板源性生长因子受体（PDGF-R）活性的化合物，最好这些化合物还可以抑制PDGF-R超家族的其他成员的活性，并且对PDGF-R超家族的成员具有选择性。PDGF-R超家族包括PDGF-R和PDGF-R相关激酶Flt和KDR。这些特色化合物在细胞培养中对降低PDGF-R活性以及最好是一个或多个PDGF-R相关激酶的活性方面是活跃的。下面描述了一个特色化合物A10（见图1a）及其在体内抑制肿瘤细胞生长的能力。通过本申请作为指南，可以获得其他能够抑制PDGF-R，最好是Flt和/或KDR的化合物。这些化合物最好用于治疗患有细胞增殖异常的患者，其特征是PDGF-R活性异常。
• Pharmacological explorations of eco-friendly amide substituted (<i>Z</i>)-β-enaminones as anti-breast cancer drugs
  作者：Palaniraja Subramamiam、Chandrasekaran Ramasubbu、Selvaraj Athiramu、Sivakumar Arumugam、Manikandan Alagumuthu

  DOI：10.1002/ardp.201800244

  日期：——

  Amide substituted (Z)‐β‐enaminones were synthesized by green chemistry and stereo‐specific synthetic pathway as novel phosphoinositide 3‐kinase (PI3K) inhibitors and breast cancer drugs. PI3K inhibition was measured by competitive ELISA. A panel of cancer cell lines including MCF‐7 (breast cancer), G‐361 (skin cancer), and HCT 116 (colon cancer) were used to assess the anticancer potentials. In the

  酰胺取代的 (Z)-β-烯胺酮通过绿色化学和立体特异性合成途径合成为新型磷酸肌醇 3-激酶 (PI3K) 抑制剂和乳腺癌药物。通过竞争性ELISA测量PI3K抑制。一组癌细胞系包括 MCF-7（乳腺癌）、G-361（皮肤癌）和 HCT 116（结肠癌）用于评估抗癌潜力。在 PI3K 测定中，2c 和 2f 对提议的抑制作用是惰性的，这从获得的 IC50 (>1.0 μM) 中可以看出。从 IC50 范围（<0.05 μM）可以看出 2a、2b 和 2d 的优异活性电位，而观察到化合物 2e 和 2i 的中间动作电位（IC50 分别为 0.1 和 0.25）。对接结果专门表明 PI3K 结合口袋中的疏水相互作用被最有效配体的结合亲和力所淹没（2a、2b 和 2d：抑制常数 Ki = 18.16、84.87 和 56.14 nM）。MTT 测定结果显示所选化合物（2a、2b 和 2d）对 MCF-7
• Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
  申请人：Sugen, Inc.

  公开号：US20040102489A1

  公开（公告）日：2004-05-27

  The present invention relates to novel heteroaryl-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.

  本发明涉及一种新型杂环基-羧酰胺，其可以调节蛋白酪氨酸激酶的活性，因此被期望在治疗异常的蛋白酪氨酸激酶活性驱动的疾病，包括癌症中有用。
• Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
  申请人：Sugen, Inc.

  公开号：US06316479B1

  公开（公告）日：2001-11-13

  The present invention relates to novel isoxazole-4-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.

  本发明涉及一种新型异噁唑-4-羧酰胺，其调节蛋白酪氨酸激酶的活性，因此预计可用于治疗由异常蛋白酪氨酸激酶活性驱动的疾病，包括癌症。